Vascular fibrosis and extracellular matrix remodelling in post-COVID 19 conditions  

作　　者：Anna Kamdar Robert Sykes Cameron R.Thomson Kenneth Mangion Daniel Ang Michelle AW Lee Tom Van Agtmael Colin Berry 

机构地区：[1]School of Cardiovascular and Metabolic Health,University of Glasgow,Glasgow G128TA,UK [2]West of Scotland Heart and Lung Centre,Golden Jubilee National Hospital,Glasgow G814DY,UK [3]Department of Cardiology,Queen Elizabeth University Hospital,NHS Greater Glasgow and Clyde Health Board,Glasgow G514TF,UK

出　　处：《Infectious Medicine》2024年第4期93-102,共10页感染医学(英文)

基　　金：Ms Anna Kamdar is supported by research funding from the British Heart Foundation MBPhD(FS/MBPhD/22/28011);Robert Sykes is supported by funding from the British Heart Foundation Centre of Research Excellence award(RE/18/6/34217);NHS Greater Glasgow and Clyde Endowment Fund-ing(GN21CA394);Cameron Thomson is supported by research funding from The University of Glasgow Doctoral Training Programme.Dr Kenneth Mangion is supported by research funding from the Chief Scientist Office(COV/LTE/20/10,COV/GLA/20/05);Ms Michelle Lee is supported by research funding from the British Heart Foundation Centre of Research Excel-lence(RE/18/6/34217);Professor Tom Van Agtmael is supported by research funding from EPSRC-Horizon Europe(EP/X031721/1[EU Ref:101072766])and MRC(MR/R005567/1);Professor Colin Berry is supported by research funding from the British Heart Foundation(FS/17/26/32744,PG/18/52-33892,RE/18/6/34217)and Medical Research Council(MR/SO18905/1).

摘　　要：Causal associations between viral infections and acute myocardial injury are not fully understood,with mech-anisms potentially involving direct cardiovascular involvement or systemic inflammation.This review explores plausible mechanisms of vascular fibrosis in patients with post-COVID-19 syndrome,focusing on extracellular matrix remodelling.Despite global attention,significant mechanistic or translational breakthroughs in the man-agement of post-viral syndromes remain limited.No effective pharmacological or non-pharmacological interven-tions are currently available for patients experiencing persistent symptoms following COVID-19 infection.The substantial expansion of scientific knowledge resulting from collaborative efforts by medical experts,scientists,and government organisations in undertaking COVID-19 research could inform treatment strategies for other post-viral syndromes and respiratory illnesses.There is a critical need for clinical trials to evaluate potential therapeutic candidates,providing evidence to guide treatment decisions for post-COVID-19 syndromes.

关 键 词：COVID-19 Post-COVID-19 syndrome Matrix remodelling Vascular dysfunction MYOCARDITIS 

分 类 号：R57[医药卫生—消化系统]